Compare TNXP & CXDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | CXDO |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.6M | 223.1M |
| IPO Year | 2008 | 1999 |
| Metric | TNXP | CXDO |
|---|---|---|
| Price | $11.09 | $7.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.20 |
| AVG Volume (30 Days) | 430.5K | ★ 673.7K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.75 | ★ 166.67 |
| EPS | N/A | ★ 0.02 |
| Revenue | $13,107,000.00 | ★ $68,167,000.00 |
| Revenue This Year | $558.11 | $45.26 |
| Revenue Next Year | $38.29 | $13.31 |
| P/E Ratio | ★ N/A | $451.50 |
| Revenue Growth | ★ 29.85 | 12.05 |
| 52 Week Low | $11.21 | $5.13 |
| 52 Week High | $69.65 | $11.23 |
| Indicator | TNXP | CXDO |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 34.80 |
| Support Level | N/A | $6.04 |
| Resistance Level | $14.85 | N/A |
| Average True Range (ATR) | 0.91 | 0.69 |
| MACD | -0.24 | -0.29 |
| Stochastic Oscillator | 3.39 | 2.14 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.